Editorial
doi: 10.1001/jamaoncol.2018.1766.
PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions
Affiliations
- PMID: 29902310
- DOI: 10.1001/jamaoncol.2018.1766
Item in Clipboard
Editorial
PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions
JAMA Oncol.
.
No abstract available
Comment on
-
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.JAMA Oncol. 2018 Oct 1;4(10):1335-1343. doi: 10.1001/jamaoncol.2018.1778. JAMA Oncol. 2018. PMID: 29902286 Free PMC article. Clinical Trial.
Similar articles
-
The Strategy of PIKing a Target: What Is AKTually Most Effective?Clin Cancer Res. 2018 May 1;24(9):2029-2031. doi: 10.1158/1078-0432.CCR-17-3440. Epub 2018 Jan 26. Clin Cancer Res. 2018. PMID: 29374052
-
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.BMC Cancer. 2019 May 14;19(1):442. doi: 10.1186/s12885-019-5668-3. BMC Cancer. 2019. PMID: 31088410 Free PMC article.
-
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer.Cancer Genomics Proteomics. 2019 May-Jun;16(3):195-206. doi: 10.21873/cgp.20125. Cancer Genomics Proteomics. 2019. PMID: 31018950 Free PMC article.
-
PI3K inhibition to overcome endocrine resistance in breast cancer.Expert Opin Investig Drugs. 2018 Jan;27(1):1-15. doi: 10.1080/13543784.2018.1417384. Epub 2018 Jan 6. Expert Opin Investig Drugs. 2018. PMID: 29252036 Review.
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review.
Cited by
-
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.BMC Cancer. 2020 Apr 23;20(1):347. doi: 10.1186/s12885-020-06810-8. BMC Cancer. 2020. PMID: 32326897 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
